title: Get a grip on immune cells by inhibiting JAKs.
abstract: JAK inhibitors are approved for myelofibrosis (MF) and polycythemia vera (PV), as they reverse inflammation-associated splenomegaly and symptoms. Notably, JAK inhibitors only marginally affect disease burden. The anti-inflammatory effects of JAK inhibitors affects DC, T and NK cells explaining their therapeutic potential for limitation of cancer-associated inflammation, Graft-versus-Host Disease (GvHD) and autoimmunity.
authors.affiliation: Department of Internal Medicine III, Oncology, Hematology and Rheumatology, University Clinic Bonn (UKB) , Bonn, Germany.
authors.forename: Kathrin
authors.initials: K
authors.lastname: Schönberg
authors.affiliation: Department of Internal Medicine III, Oncology, Hematology and Rheumatology, University Clinic Bonn (UKB) , Bonn, Germany.
authors.forename: Janna
authors.initials: J
authors.lastname: Rudolph
authors.affiliation: Department of Internal Medicine III, Oncology, Hematology and Rheumatology, University Clinic Bonn (UKB) , Bonn, Germany.
authors.forename: Sowmya Parampalli
authors.initials: SP
authors.lastname: Yajnanarayana
authors.affiliation: Department of Internal Medicine III, Oncology, Hematology and Rheumatology, University Clinic Bonn (UKB), Bonn, Germany; Laboratory for Tumorimmunology, Department of Medicine V, Medical University Innsbruck, Innsbruck, Austria.
authors.forename: Dominik
authors.initials: D
authors.lastname: Wolf